5 ESSENTIAL ELEMENTS FOR SEVITERONEL TNBC

Much like TNBC, the position of AR during the management of estrogen receptor-positive (ER+) breast cancer is a location of active exploration. AR is expressed in approximately ninety% of ER+ tumors and preclinical knowledge implies that AR expression is associated with resistance to the two tamoxifen and aromatase inhibitors in ER+ mobile strains